These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2324 related items for PubMed ID: 21757258

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
    Song C, Kim YS, Hong JH, Kim CS, Ahn H.
    BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
    [Abstract] [Full Text] [Related]

  • 7. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 9. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Mottet N.
    Eur Urol; 2021 Feb 15; 79(2):263-282. PubMed ID: 33039206
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F.
    Bull Cancer; 2006 Sep 15; 93(9):949-58. PubMed ID: 16980238
    [Abstract] [Full Text] [Related]

  • 12. Treatment options in androgen-independent prostate cancer.
    Lara PN, Meyers FJ.
    Cancer Invest; 1999 Sep 15; 17(2):137-44. PubMed ID: 10071598
    [Abstract] [Full Text] [Related]

  • 13. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J, Altwein JE.
    Aktuelle Urol; 2009 Mar 15; 40(2):100-8. PubMed ID: 19253209
    [Abstract] [Full Text] [Related]

  • 14. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.
    Int J Radiat Oncol Biol Phys; 2012 Aug 01; 83(5):1493-9. PubMed ID: 22401922
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 01; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 16. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E, Tekyi-Mensah S, Hart K, Bolton S, Forman J.
    Am J Clin Oncol; 2003 Oct 01; 26(5):e119-23. PubMed ID: 14528085
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, European Association of Urology.
    Eur Urol; 2011 Jan 01; 59(1):61-71. PubMed ID: 21056534
    [Abstract] [Full Text] [Related]

  • 19. EAU guidelines on prostate cancer.
    Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F, European Association of Urology.
    Eur Urol; 2005 Oct 01; 48(4):546-51. PubMed ID: 16046052
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 117.